PRostate Imaging Self-assessment and Mentoring Scheme
What to expect?
Prostate cancer is the most common cancer in men. As the initial PSA blood test is not very specific, many men with a raised PSA level are referred to have TRUS biopsy to determine whether they have potential cancer. Many of these biopsies could be avoided with better detection and a more specific test. The UK PROMIS trial examined the diagnostic accuracy of multi-parametric MRI (mpMRI) and TRUS biopsy in prostate cancer and demonstrated that mpMRI prior to first prostate biopsy reduces the detection and overtreatment of insignificant cancer as well as the number of men who need biopsies.
The PRostate Imaging Self-assessment and Mentoring (PRISM) scheme, developed in collaboration with and funded by Prostate Cancer UK, is a web-based self-assessment and continuous learning platform that aims to help prostate mpMRI readers across the UK to develop their expertise in interpreting mpMRI images.
External links to organisations and institutions in related areas of work:
We presented at the:
– 25th European Congress of Radiology (ECR) 2019, 27 February – 3 March 2019 in Vienna, Austria –
– SPIE Medical Imaging, 16 -21 February 2019 in California, USA –
– European Society of Urogenital Radiology (ESUR), 13 – 16 September 2018 in Barcelona, Spain –
PRISM reflects very well what we do in our clinical practice.
DR FAYE CUTHBERT, CONSULTANT RADIOLOGIST, BRIGHTON AND SUSSEX UNIVERSITY HOSPITALS NHS TRUST
COVID-19 Training SetFIND OUT MORE
PERFORMSFIND OUT MORE
MyPeBSFIND OUT MORE
PROSPECTSFIND OUT MORE
Digital Pathology TrialFIND OUT MORE
Breast Pathology EQAFIND OUT MORE
Lung Cancer ScreeningFIND OUT MORE
Grand ChallengeFIND OUT MORE
Breast AssessmentFIND OUT MORE
IMPROVEFIND OUT MORE
PERFORMS InternationalFIND OUT MORE